News from the World of Clinical Research

Site Enablement: How Sponsors and CROs Can Enhance Their Clinical Trials in a Competitive Landscape

The evolution of clinical research has been dependent on the conversion of Healthcare Organizations (HCOs) to clinical research sites, along with the conversion of Healthcare Providers (HCPs) to Princ…

Opening doors

Following in their footsteps – the young people choosing to follow their parents into the pharmaceutical industry

Pharma has changed a lot in recent years. The rules and regulations surrounding develo…

J&J to phase out Janssen name in corporate rebrand

Janssen, a brand name that for six decades has been emblazoned on Johnson & Johnson’s pharmaceutical laboratories and prescription drugs, will be phased out as part of a corporate rebranding in th…

NICE gives green light for MSD's Keytruda

The decision is the first verdict based on data from a wider immunotherapy ‘basket’ study

MSD has revealed that the National Institute for Health and Care Excellence (NICE) has recommended the use of …

Biogen kicks off 1,000 layoffs as part of CEO Chris Viehbacher's 'complete redesign'

It was only last spring that Biogen started a round of layoffs that eventually shrank the company’s head count by nearly 900 people last year. Now, a fresh round of job cuts targeting 1,000 positions …

Men with enlarged prostates offered robotic treatment by fourth University Hospital

Aquablation is a robotic method that uses a high-pressure saline solution to remove tissue

The Norfolk and Norwich University Hospitals (NNUH) Urology team have become the first in the East of England…

Autumn Ethics & GCP Forum - ONLINE - Friday 17th November 2023

To book via Eventbrite and see the full agenda visit our Website

If you have any questions please email office@icr-global.org 

Green light for one of Europe’s largest life sciences campus

Reef Group and UBS Asset Management have gained approval to develop one of Europe’s largest life sciences campuses in Stevenage, UK.

Family of Henrietta Lacks sues Ultragenyx over use of HeLa cell line

The family of Henrietta Lacks is suing rare disease drug developer Ultragenyx over its use of technology built from her cells, which were taken without her knowledge or consent in 1951 and immortalize…

Cannabinoid company expands into oncology

Oxford Cannabinoid Technologies Holdings (OCTP) – the company developing prescription cannabinoid medicines – is expanding its research and development plans into oncology. The decision comes after it…

Build a More Participant-Focused Trial: Amplify the Patient Voice in Clinical Research Technology Development

For those of us who use sophisticated digital tools every day, it’s easy to assume that technology always makes life easier. It doesn’t.

TauRx’s deliver Alzheimer’s disease therapy results

TauRx Pharmaceuticals – a company focused on Alzheimer’s disease (AD) research – has announced results from its pivotal phase 3 LUCIDITY trial.

The study measured the effect of hydromethylthionine mes…

Improving the Patient Experience Through Research-Driven Design

Digital technologies designed to support clinical trial management have evolved greatly over the years, spurred by increasing complexity in study design, emerging technologies in specific therapeutic …

FDA grants Eisai’s Leqembi full approval, opening door to wider use of Alzheimer’s drug

On Thursday, the Food and Drug Administration awarded a full approval to the Alzheimer’s disease treatment Leqembi, a decision expected to significantly increase use of the therapy and, potentially, o…

How to Harmonize and Interpret the Tsunami of Sensor Data in Clinical Trials

The surge of wearable sensors is transforming the clinical trial experience for patients, sponsors, and research sites. Sensors can be worn by the patient 24/7 to capture physiology continuously, prov…

Oh my, it’s AI!

How can we create trust in AI across the vast pharmaverse?

The proliferation of AI/ChatGPT resources during the initial months of 2023 has raised several questions across the pharma industry around it…

'The Top Line': The American Diabetes Association's annual conference, plus this week's headlines

In this episode of "The Top Line," we talk with Fierce’s Andrea Park and Gabrielle Masson about the latest from the American Diabetes Association's annual conference. We also cover a statement about t…

With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy

BioMarin Pharmaceutical, having secured a long-awaited approval from the Food and Drug Administration, says its focus has now turned to launching its new hemophilia gene therapy in the U.S. market.

Eli Lilly's Mounjaro is primed to overtake Novo Nordisk's popular diabetes and obesity duo: report

In the battle for superiority in the field of next-gen diabetes and obesity treatments, Novo Nordisk holds the lead as the developer of the metabolism-regulating treatment semaglutide.

FDA delays decision on GSK bone cancer drug acquired in $2B buyout

• The Food and Drug Administration has delayed an approval decision for an experimental drug GSK is developing for a type of bone marrow cancer, so it can review new data submitted by the pharmaceutica…

MARKETING 'Scrolling Therapy' for Eurofarma by Dentsu Creative nabs Cannes Lions Pharma Grand Prix as traditional players lose out, again

Last year, the top winners at the prestigious Pharma Lions event at Cannes were not in fact pharma companies, and in 2023 that trend continues as a digital face-tracking app, a breast cancer inequalit…